Related Experiment Video
Updated: Feb 25, 2026

Minimal Erythema Dose MED Testing
Published on: May 28, 2013
Update in clinical science: MASLD in children and adolescents
Sander Lefere1, Bart G P Koot2, Jake P Mann3
1Hepatology Research Unit, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium; Liver Research Center Ghent, Ghent University Hospital, Ghent, Belgium.
None:
Paediatric metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly common liver disease, with an estimated global prevalence of up to 7.5% and growing concern regarding hepatic and extrahepatic complications even in early life. In this paper, we review recent advances in epidemiology, genetics, early-life risk factors, natural history and comorbidities, focusing on emerging data published in the last 3 years. We also outline a practical approach to the management of MASLD in children, integrating newly developed non-invasive tests. Lastly, we highlight key research questions to be studied in the coming years.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Diagnostic and Statistical Manual of Mental Disorders (DSM)
Therapeutic Drug Monitoring: Affecting Factors
Mitral Stenosis III: Medical Management
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
